MEDICAL

HealthMyne's Radiomic Technology Leveraged to Identify Biomarkers That Predict Immunotherapy Treatment Responses

HealthMyne | September 22, 2021

HealthMyne, a pioneer in applied radiomics, announced that peer-reviewed research recently published in the journal Cancers has demonstrated the ability of its radiomics technology to identify biomarkers that predict whether patients with lung adenocarcinoma would benefit from immunotherapy.

In the Cancers article, researchers led by Vincenza Granata evaluated HealthMyne's technology as a quantitative imaging decision support tool for radiomic analysis of lung adenocarcinoma in chest CT scans. Researchers analyzed radiomic biomarkers to predict Overall Survival (OS) and Progression Free Survival (PFS) time.

To perform the study, researchers selected 74 patients with histologically confirmed lung cancer who underwent immunotherapy and compared them with 50 patients with histologically confirmed lung adenocarcinoma who underwent chemotherapy alone or in combination with targeted therapy.

Researchers segmented each patient's lesion leveraging HealthMyne's advanced imaging analytics solution to extract 573 radiometric metrics from the cohort images to predict OS and PFS time. Researchers found that 19 radiomic features were significant for predicting OS and 108 radiomic features for predicting PFS time.

Researchers concluded that the study demonstrated the relationship between radiomics and immunotherapeutic response and that specific radiomic features can be used to select patients with lung adenocarcinoma who would benefit from immunotherapy.

To maximize the value of research and development investments, drug developers need an accurate and efficient means of selecting and stratifying patients for clinical studies. Numerous examples of peer-reviewed research have shown that radiomics and precision image analysis identifies biomarkers that drive greater personalization of treatment and provides new insights for better decisions. At HealthMyne, we strive to develop innovative radiomic solutions that contribute to the advancement of this critical body of evidence.

- Rose Higgins, CEO, HealthMyne.

About HealthMyne
HealthMyne® is a pioneer in applied radiomics, the cutting-edge field of extracting novel data and biomarkers from medical images. Our FDA-approved and CE marked, AI-enabled solutions allow organizations to easily access and translate groundbreaking radiomic insights into use in research, clinical outcomes, and treatment pathways. By leveraging radiomics, our clients and partners can accelerate the development and delivery of the best possible treatments. HealthMyne's approach is based upon the premise that every cancer patient's story begins with an image. We believe that unleashing the hidden power of imaging data and radiomics will revolutionize personalized care -- ensuring the right treatment every time. Our mission is to advance precision health initiatives through accessible and translatable radiomic data.

Spotlight

A video detailing the world leading seed and biotechnology research being undertaken at Royal Holloway, University of Londo

Spotlight

A video detailing the world leading seed and biotechnology research being undertaken at Royal Holloway, University of Londo

Related News

MEDTECH

Roche Signs an Agreement with Sysmex to Bring Haematology Testing Innovations Globally

Roche | January 25, 2021

Roche declares that, on 14 December, 2020, it marked a Global Business Partnership Agreement* (GBP) with Sysmex. Under this new system, the gatherings restored their obligation to the long standing Distribution, Sales and Service (DSS) arrangement, permitting Roche to keep on disseminating Sysmex hematology items, including instruments and reagents. This GBP sees the presentation of an IT Solutions Collaboration Agreement. In the recently characterized joint effort, the two organizations have consented to use their separate IT stages to improve client experience, in the short to mid-term, with a more drawn out term aspiration to utilize the IT frameworks to prompt improved clinical dynamic. The GBP arrangement will run until the finish of 2030. “Roche is committed to supporting improvements in haematology testing, which helps patients with the diagnosis and management of blood diseases, as diverse as anemia and leukaemia”, said Thomas Schinecker, CEO Roche Diagnostics. “Extending our longstanding partnership with Sysmex underscores our unique synergy and our objective to offer our customers high-quality haematology solutions to improve the testing efficiency in central laboratories in hospitals and commercial laboratories, ultimately benefiting the millions of patients living with blood disorders.” The burden of blood disorders is exceptionally high, for patients as well as for society overall. Ongoing examinations assessed that, in Europe, 80 million individuals experience the ill effects of hematological issues and the monetary effect of blood issues in Europe adds up to EUR 23 billion every year, generally in medical services use. Improved administration is a vital factor to neutralize the ascent of this monetary weight for healthcare and society.

Read More

INDUSTRIAL IMPACT

Kane Biotech Announces New Collaboration Agreements for Prosthetic Joint Infection, expanding its DispersinB® applications

Kane Biotech Inc. | February 11, 2022

Kane Biotech Inc. announces that it has signed collaboration agreements with Dr. James Doub, MD, Assistant Professor of Medicine, University of Maryland School of Medicine’s Institute of Human Virology, and the University of Texas Medical Branch (UTMB) to study the use of DispersinB® with Prosthetic Joint Infection (PJI) patients. The group is securing funding from the National Institutes of Health (NIH) for pre-clinical work to be done by Josh Wenke, a Professor in the Department of Orthopedic Surgery and Rehabilitation at UTMB. PJI’s are one of the most serious complications of joint replacement surgery. Conservative estimates are that approximately 1–2% of all prostheses will become infected over the life of the implant [1]. The financial burden of treating these infections is staggering. It is estimated that they will cost the US healthcare system $1.62 billion in 2020 [1]. In addition, patients have significant morbidity and mortality as a direct result of our current medical and surgical management to treat these infections [2]. In one study, the five-year mortality for prosthetic joint infections is over 20% [2]. “These collaborations are of utmost importance given our shared strategies for managing complex musculoskeletal infections and finding cures for the debilitating morbidity associated with PJI. We are highly optimistic of advancing this field scientifically and clinically for the benefit of patients across the globe” Marc Edwards, CEO of Kane Biotech “The Institute of Human Virology has been testing the use of bacteriophage therapeutics in treating recalcitrant PJIs with some early signals of success,” explained Dr. Doub, who is also Director of Infectious Diseases Ambulatory Practice at the University of Maryland Medicine Center. “However, DispersinB®, has properties that bacteriophages do not have which include superior application as a preventative therapeutic, broader spectrum of activity, and a much easier regulatory (FDA) path.” Dr. Doub is a consultant for Kane Biotech. Dr. Nanda Yakandawala, Vice President of Research and Development at Kane, in collaboration with Dr. Doub and Josh Wenke, Ph. D, recently submitted a R-21 grant application to NIH to fund pre-clinical work to be performed by Dr. Wenke. About University of Texas Medical Department Established in 1891 as the University of Texas Medical Department, UTMB was the nation's first public medical school and hospital under unified leadership and has evolved into a modern academic health science center with multiple campus locations and almost 1,000 faculty members educating approximately 3,500 students. Since the beginning, UTMB has been at the forefront of medical research, with researchers studying the viruses common to a sub-tropical island climate. Today, our world-renowned investigators generate a portfolio exceeding $160 million, and work in state-of-the-art laboratories developing diagnostic tools, cures and vaccines to benefit the global community. About Kane Biotech Kane Biotech is a biotechnology company engaged in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property (81 patents and patents pending, trade secrets, and trademarks) and products developed by the company's own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex™, bluestem™, bluestem®, silkstem™, goldstem™, coactiv+™, coactiv+®, DermaKB™ and DermaKB Biofilm™ are trademarks of Kane Biotech Inc.

Read More

CELL AND GENE THERAPY

Evonetix Demonstrates Novel Enzymatic DNA Synthesis Method

EVONETIX LTD | March 02, 2022

EVONETIX LTD the synthetic biology company bringing semiconductor technology to DNA synthesis, announced it has achieved enzymatic DNA synthesis capability with its proprietary, thermally controlled synthesis chemistry. The culmination of a three-year development program, supported by Innovate UK and in collaboration with Durham University, the results demonstrate that Evonetix’s unique, semiconductor array-based platform is compatible with both chemical and enzymatic DNA synthesis, enabling the production of scarless DNA sequences that are directly compatible with downstream processing. Synthetic biology is expected to impact many industries, but the production of high-fidelity DNA at scale, without the need for post-synthesis error correction, has remained a challenge. Evonetix‘s unique approach re-engineers traditional phosphoramidite synthesis chemistry to use thermal, rather than acidic, control of deprotection reactions. This approach enables parallel synthesis of thousands of sequences on a single chip. The research was directed by Dr Raquel Sanches-Kuiper, VP of Technology at Evonetix, whose enzyme engineering team has focussed on the development of enzymes that can incorporate Evonetix modified nucleotides efficiently. The programme was completed in collaboration with Dr David Hodgson, Associate Professor of Chemistry at Durham University, whose group was involved in developing the modified nucleotides for enzymatic synthesis in Evonetix silicon arrays. “We have, for the first time, demonstrated thermally controlled enzymatic DNA synthesis. Our approach brings together thermally controlled synthesis and error detection, allowing for high-throughput assembly of high-fidelity gene-length DNA at scale. Our synthesis platform can now be used with both enzymatic and chemical synthesis, allowing us to smoothly integrate our enzymatic approach as this technology develops. Our unique, on-chip, synthesis and error correction platform will overcome many of the existing challenges in current approaches to de novo gene synthesis.” Dr Raquel Sanches-Kuiper, VP of Technology at Evonetix Dr David Hodgson, Associate Professor of Chemistry at Durham University, added: “We have been able to combine our world leading expertise in nucleotide chemistry with the novel Evonetix approach for enzymatic DNA synthesis, enabling cleaner, simpler synthesis reactions that will ultimately allow for scaled production of high-quality synthetic DNA with revolutionary applications across industry and research.” Simon Rowland, Innovate UK, commented “Engineering Biology was identified in the 2021 UK Innovation Strategy as one of the key technologies that will deliver future economic success in the UK. The rapidly growing synthetic biology market is estimated to reach $40 billion by the mid-2020s. Innovate UK supports businesses and research institutions to drive business investment into R&D and is proud to have supported Evonetix and the development of this game changing innovation in DNA synthesis.”

Read More